Up to 50,000 New Zealanders per year will benefit from a new multiproduct agreement PHARMAC has reached with Novartis, which makes more funded medicines available for a wide range of health conditions.

Thousands of New Zealanders will benefit from advances in treatment as a result of two PHARMAC funding decisions. The first decision is to fund a medication for treating a degenerative eye condition, and the second is to fund another oral anticoagulant option for the prevention of strokes and the prevention or treatment of blood clots.